
Surmodics SRDX
Quarterly report 2025-Q2
added 08-08-2025
Surmodics Total Assets 2011-2026 | SRDX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 179 M | 186 M | 158 M | 195 M | 169 M | 160 M | 164 M | 137 M | 133 M | 98.7 M | 105 M | 102 M | 103 M | 163 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 98.7 M | 146 M |
Quarterly Total Assets Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 163 M | 164 M | 179 M | 177 M | 183 M | 180 M | 186 M | 189 M | 166 M | 170 M | 158 M | - | 184 M | 185 M | 195 M | 177 M | 195 M | 164 M | 169 M | 169 M | 169 M | 155 M | 160 M | 160 M | 160 M | 151 M | 164 M | 164 M | 164 M | 135 M | 137 M | 137 M | 137 M | 129 M | 133 M | 133 M | 133 M | 112 M | 98.7 M | 98.7 M | 98.7 M | 87.1 M | 105 M | 105 M | 105 M | 95.1 M | 102 M | 102 M | 102 M | 108 M | 104 M | 104 M | 103 M | 152 M | 157 M | 157 M | 157 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 87.1 M | 145 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 15.85 | -2.49 % | $ 171 M | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Agilent Technologies
A
|
10.7 B | $ 115.06 | -0.29 % | $ 35 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
73.6 M | $ 1.13 | -2.59 % | $ 6.15 M | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 16.05 | -3.83 % | $ 855 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 2.3 | - | $ 10.2 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 23.13 | -1.28 % | $ 642 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 175.65 | 0.06 % | $ 8.71 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 493.53 | -1.59 % | $ 14.2 B | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 189.61 | -1.7 % | $ 135 B | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 120.93 | -2.22 % | $ 19.2 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.35 | -2.03 % | $ 403 M | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 14.43 | -3.93 % | $ 436 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 7.69 | -3.17 % | $ 985 M | ||
|
Guardant Health
GH
|
2.01 B | $ 78.6 | -9.83 % | $ 9.85 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 2.69 | -1.82 % | $ 87.3 K | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.13 | -0.9 % | $ 4.89 M | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 28.31 | 0.62 % | $ 20 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 106.81 | 0.1 % | $ 8.81 B | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 260.93 | -4.51 % | $ 21.7 B | ||
|
Natera
NTRA
|
1.39 B | $ 193.03 | -4.91 % | $ 19 B | ||
|
Celcuity
CELC
|
467 M | $ 117.14 | -6.02 % | $ 5.48 B | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 80.59 | -1.03 % | $ 5.44 B | ||
|
Senseonics Holdings
SENS
|
126 M | $ 6.68 | 0.15 % | $ 279 M | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Soleno Therapeutics
SLNO
|
564 M | $ 52.63 | 0.23 % | $ 2.67 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 191.51 | -3.19 % | $ 21.3 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.42 | -6.13 % | $ 2.04 B | ||
|
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.94 | -6.97 % | $ 3.89 M | ||
|
Neuronetics
STIM
|
142 M | $ 1.35 | -2.17 % | $ 89 M | ||
|
National Research Corporation
NRC
|
135 M | $ 16.48 | -3.34 % | $ 369 M |